36 related articles for article (PubMed ID: 1801881)
1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
Arias-Martinez A; Martínez de Castro E; Gallego J; Arrazubi V; Custodio A; Fernández Montes A; Diez M; Hernandez R; Limón ML; Cano JM; Vidal-Tocino R; Macias I; Visa L; Martin Richard M; Sauri T; Hierro C; Gil M; Cerda P; Martínez Moreno E; Martínez Lago N; Mérida-García AJ; Gómez González L; García Navalón FJ; Ruiz Martín M; Marín G; López-López F; Ruperez Blanco AB; Fernández AF; Jimenez-Fonseca P; Carmona-Bayonas A; Alvarez-Manceñido F
Clin Transl Oncol; 2024 Feb; ():. PubMed ID: 38361134
[TBL] [Abstract][Full Text] [Related]
2. A Peptidic Thymidylate-Synthase Inhibitor Loaded on Pegylated Liposomes Enhances the Antitumour Effect of Chemotherapy Drugs in Human Ovarian Cancer Cells.
Marverti G; Gozzi G; Maretti E; Lauriola A; Severi L; Sacchetti F; Losi L; Pacifico S; Ferrari S; Ponterini G; Leo E; Costi MP; D'Arca D
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32585842
[TBL] [Abstract][Full Text] [Related]
3. High efficacy of combination chemotherapy with S-1 and low-dose docetaxel for the treatment of highly advanced gastric cancer with peritoneal dissemination: A case report.
Zhu L; Luo W; Wei J; Zou C
Oncol Lett; 2013 May; 5(5):1509-1512. PubMed ID: 23761814
[TBL] [Abstract][Full Text] [Related]
4. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Gómez-Martin C; Sánchez A; Irigoyen A; Llorente B; Pérez B; Serrano R; Safont MJ; Falcó E; Lacasta A; Reboredo M; Aparicio J; Dueñas R; Muñoz ML; Regueiro P; Sanchez-Viñes E; López RL
Clin Transl Oncol; 2012 Sep; 14(9):689-97. PubMed ID: 22855151
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.
Nishioka N; Matsuoka T; Yashiro M; Hirakawa K; Olden K; Roberts JD
Cancer Sci; 2012 Feb; 103(2):228-32. PubMed ID: 22098548
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer.
Hara T; Nishikawa K; Sakatoku M; Oba K; Sakamoto J; Omura K
Gastric Cancer; 2011 Oct; 14(4):332-8. PubMed ID: 21465339
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of haptaplatin/5-FU and leucovorin for advanced stomach cancer.
Lee WS; Lee GW; Kim HW; Lee OJ; Lee YJ; Ko GH; Lee JS; Jang JS; Ha WS
Cancer Res Treat; 2005 Aug; 37(4):208-11. PubMed ID: 19956515
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for advanced gastric cancer: slow but further progress.
Kim YH
Cancer Res Treat; 2005 Apr; 37(2):79-86. PubMed ID: 19956484
[TBL] [Abstract][Full Text] [Related]
9. Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.
Lordick F; Jäger D
Gastrointest Cancer Res; 2008 Jul; 2(4):187-97. PubMed ID: 19259285
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
Nakayama N; Koizumi W; Tanabe S; Sasaki T; Saigenji K
Gastric Cancer; 2006; 9(3):185-91. PubMed ID: 16952036
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for gastric cancer.
Sastre J; Garcia-Saenz JA; Diaz-Rubio E
World J Gastroenterol; 2006 Jan; 12(2):204-13. PubMed ID: 16482619
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
De Vita F; Orditura M; Matano E; Bianco R; Carlomagno C; Infusino S; Damiano V; Simeone E; Diadema MR; Lieto E; Castellano P; Pepe S; De Placido S; Galizia G; Di Martino N; Ciardiello F; Catalano G; Bianco AR
Br J Cancer; 2005 May; 92(9):1644-9. PubMed ID: 15856038
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer.
Min YJ; Bang SJ; Shin JW; Kim DH; Park JH; Kim GY; Ko BK; Choi DH; Cho HR
J Korean Med Sci; 2004 Jun; 19(3):369-73. PubMed ID: 15201502
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Tsujitani S; Fukuda K; Kaibara N
Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
[TBL] [Abstract][Full Text] [Related]
15. Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen.
Cascinu S; Baldelli AM; Catalano V; Giordani P; Beretta GD; Silva RR; Gasparini G; Mari D; Maisano R; Salvagni S; Barni S; Labianca R; Frontini L; Curti C; Catalano G
Br J Cancer; 2002 Jan; 86(2):213-7. PubMed ID: 11870508
[TBL] [Abstract][Full Text] [Related]
16. A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.
Eatock MM; Anthony DA; El-Abassi M; Wilson P; Paul J; Smith M; Soukop M; Evans TR
Br J Cancer; 2000 Jun; 82(12):1925-31. PubMed ID: 10864199
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.
Poorter RL; Bakker PJ; Veenhof CH
Pharm World Sci; 1998 Apr; 20(2):45-59. PubMed ID: 9584337
[TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.
González-Barón M; Feliu J; Espinosa E; García-Girón C; Chacón I; Garrido P; Colmenarejo A; Ordóñez A; Zamora P
Cancer Chemother Pharmacol; 1995; 36(3):255-8. PubMed ID: 7781148
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial.
Lacave AJ; Barón FJ; Antón LM; Estrada E; De Sande LM; Palacio I; Esteban E; Gracia JM; Buesa JM; Fernández OA
Ann Oncol; 1991; 2(10):751-4. PubMed ID: 1801881
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
